

31/01/2024

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400001

Dear Sir,

Sub: Outcome of the Board Meeting under Regulation 30 and 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

BSE Code: 531210

We would like to inform you that, the Board of Directors of the Company at their meeting held today i.e. **31st January, 2024** has, inter alia considered and approved Unaudited Financial Results (as per IND-AS) for the quarter and nine-months ended on **31st December, 2023**.

Enclosed herewith a copy of the same along with a copy of **Limited Review Report dated 31st Jan, 2024** received from **M/s. Vora & Associates**, Chartered Accountants, Statutory Auditors of the Company with respect to Unaudited Financial Results for the quarter and nine-months ended on **31st December, 2023**.

The Meeting commenced at 3:30 p.m. and concluded at 5.30 p.m.

This is for your information and record.

Thanking you,

Yours faithfully,

FOR COLINZ LABORATORIES LTD

DR. MANI L. S.
Chairman of the Meeting



Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Mobile : 9137392123



Independent Auditor's Review Report on Unaudited Quarterly Financial Results

To
The Board of Directors,
COLINZ LABORATORIES LIMITED.

We have reviewed the accompanying statement of unaudited financial results ('the Statement') of **COLINZ LABORATORIES LIMITED** ('the Company') for the quarter and nine months ended 31st December, 2023 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

This statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34') prescribed u/s 133 of the Companies Act, 2013 ('the Act'), SEBI Circular CIR/CF/FAC/62/2016 dated 05/07/2016 (hereinafter referred to as the 'the SEBI Circular') and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Statements Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Act read with relevant Rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For VORA & ASSOCIATES
CHARTERED ACCOUNTANTS
(ICAI Firm Reg. No.: 111612W)


RONAK A. RAMBHIA
PARTNER

(Membership No.: 140371)



UDIN: 24140371BKAKSR5379
PLACE: MUMBAI
DATED: January 31, 2024

COLINZ LABORATORIES LIMITED.

(CIN NO: L24200MH1986PLC041128)

A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED "" 31ST DECEMBER-2023""

""(Rupees in Lakhs)""

S. No.	PARTICULARS	UN-AUDITED					AUDITED
		QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		31-Dec-2023	30-Sep-2023	31-Dec-2022	31-Dec-2023	31-Dec-2022	31-Mar-2023
PART-I							
1	(a) Revenue from Operation	171.45	178.62	167.96	540.01	543.42	715.49
2	(b) Other Income	4.78	7.59	4.30	16.80	12.94	17.21
3	Total Revenue from Operation (a+b)	176.23	186.21	172.26	556.81	556.36	732.70
4	Expenses						
	a Cost Of Material Consumed	8.89	15.72	12.03	41.85	58.40	61.78
	b Purchase of Stock in Trade	36.68	49.48	47.34	122.79	125.56	170.85
	c Change in Inventories Of Finished Goods and Work in Progress of Stock in trade.	8.57	(7.72)	(9.40)	6.96	(11.44)	(3.32)
	d Employee Benefit Expenses	76.11	80.09	76.58	235.16	232.27	303.43
	e Finance Cost	1.02	0.92	1.38	2.75	3.93	5.23
	f Depreciation & Amortisation Expenses	3.26	3.26	3.22	9.78	9.67	12.89
	g Other Expenses	27.07	28.39	27.85	91.45	93.77	121.86
	Total Expenses	161.60	170.14	159.00	510.74	512.16	672.72
5	Profit /(Loss) Before exceptional items and tax (3-4)	14.63	16.07	13.26	46.07	44.20	59.98
6	Exceptional items						
7	Profit /(Loss) before tax (5-6)	14.63	16.07	13.26	46.07	44.20	59.98
8	Tax Expenses (Provision for Taxation) Current tax						
	i) Current Tax	4.00	3.75	3.00	11.00	11.25	15.80
	ii) Tax for earlier years	-	-	-	-	-	(1.56)
	iii) MAT Credit of Earlier years	-	-	-	-	-	-
	iv) Deffered Tax	-	-	-	-	-	-
9	Profit /(Loss) for the period from continuing	10.63	12.32	10.26	35.07	32.95	45.74
10	Profit /(Loss) from discontinued operations	-	-	-	-	-	-
11	Tax expenses of discontinued operations	-	-	-	-	-	-
12	Profit /(Loss) for the period (9+10-11)	10.63	12.32	10.26	35.07	32.95	45.74
13	Other Comprehensive Income (NET OF TAX)						
	A) i) Item that will not be reclassified to Profit or Loss	11.30	3.42	(1.75)	26.12	2.25	(0.57)
	ii) Income tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-	-
14	Total Comprehensive Income for the period (12+13) Comprising Profit /(Loss) and Other Comprehensive	21.93	15.74	8.51	61.19	35.20	45.17
15	Earning per equity share (for Continuing operation)						
	i) Basic	0.42	0.49	0.41	1.39	1.31	1.82
	ii) Diluted	0.42	0.49	0.41	1.39	1.31	1.82



Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com


Mobile : 9137392123

NOTES TO THE FINANCIAL RESULTS :-

- 1) The above financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on 31st Jan, 2024.
- 2) The above results of the Company has been reviewed by the Statutory Auditors and they have issued a Limited Review Report on the same.
- 3) The Company is primarily engaged in the business of manufacturing Pharmaceutical Formulations and there is no other reportable segment.
- 4) Previous figures have been regrouped/ rearranged , wherever necessary.
- 5) This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

For and on behalf of the Board
COLINZ LABORATORIES LTD.

CIN NO : L24200MH1986PLC041128


Dr. MANI L. S.
(Chairman of the Meeting)
(DIN NO : 00825886)



MUMBAI
31st Jan, 2024



Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Mobile : 9137392123